Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 17 Mar 2023
Germany: Activation of bitter taste receptors opens lung pathways, making them potential targets for the treatment of chronic lung diseases...
Read Full NewsIn a pilot study — the first to test CAR-T therapy in smoldering multiple myeloma — patients with high-risk disease remained MRD-negative for more than 15 months. But is it a cure?
New research shows how certain orphan noncoding RNA — oncRNA — can be predictable enough to be a ‘bar code’ identifying specific cancers. Liquid biopsy could be next.
A phase 3 study investigates the outcomes associated with intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia.
A single-arm study hints at an uptick in pathologic complete responses when a CD39 blocker is added to perioperative durvalumab and chemotherapy for NSCLC.
A study of a real-world population underscores measurable residual disease thresholds indicative of the risk for relapse in NPM1-mutated AML, suggesting guidance in treatment decisions.
1.
An "exploding" field of antibody-drug conjugates is making progress against ovarian cancer.
2.
Telehealth in the pandemic era resulted in fewer therapy interruptions.
3.
Clinical trial is testing whether heavy lifting could combat cancer side effects
4.
In high-risk muscle invasive urothelial cancer, adjuvant pembrolizumab improves disease-free survival.
5.
Rural colon cancer patients face higher risks, but minimally invasive surgery could narrow gap
1.
AI Meets the Gut Microbiome: Early Detection of GI Malignancies Redefined
2.
The Growing Crisis of Aplastic Anemia: A Call for Action
3.
Understanding Drug-Induced Cardiotoxicity: Mechanisms, Impact, and Future Directions
4.
Revolutionizing Cancer Treatment: The Promise of Bevacizumab Injections
5.
Unlocking the Potential of Leukemia Treatment: A New Hope for Patients
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VIII
2.
Benefits of Treatment with CDK4/6 Inhibitors in HR+/HER2- aBC in Clinical Trials and the Real World
3.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part IV
4.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part II
5.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part II
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge